Two titans are speeding change
Both retail titans are moving with alacrity to reinvent their core business, even as they invest billions of dollars in other relevant fields — most notably artificial intelligence.
Jeffrey Woldt
PBM reform: The end of the beginning
The recent release of an interim report by the Federal Trade Commission about what the agency characterizes as “prescription drug middlemen” represents a vindication of sorts for pharmacy advocates who have long contended that PBMs employ business practices that skew the market to their advantage.